mash wegovy - Search News

Order byBest matchMost fresh

Wegovy, FDA and Novo

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

BioPharma Dive · 17h

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

Managed Healthcare Executive · 17h

FDA Grants Accelerated Approval of Wegovy to Treat Liver Disease

· 17h

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

He explained that one in three overweight or obese people suffer from it, with some 22 million Americans among them.

· 7h

NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?

· 20h

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

Medscape19h

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis but without cirrhosis.

Investor's Business Daily on MSN10h

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.

BioSpace18h

Novo Wins MASH Approval for Wegovy

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according to analysts at BMO Capital Markets.

Healio13h

FDA approves Wegovy for certain adults with noncirrhotic MASH

The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.Semaglutide 2.4 mg injection (Wegovy,

Pharmaceutical Technology on MSN19h

Wegovy becomes first GLP-1RA to gain FDA MASH approval

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Health and Me on MSN4h

Wegovy Approved For MASH Treatment With Fibrosis But No Cirrhosis

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated steatohepatitis (MASH) in adults. Know how the approval was given and what it means for Wegovy's future as a weightloss and diabetes drugs.